Helicobacter pylori eradication: Sequential and traditional therapy

Gastroenterology and Hepatology

Volumn 5, Issue 1, 2009, Pages 59-64

  Vakil, Nimish ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Dyspepsia; Helicobacter pylori; Peptic ulcer disease; Quadruple therapy; Sequential therapy; Triple therapy

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL GENE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; ERADICATION THERAPY; FRAMESHIFT MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LEUKOPENIA; PEPTIC ULCER; RDXA GENE; REVIEW; SALVAGE THERAPY; STOMACH EMPTYING; STOMACH LYMPHOMA; STOMACH MUCUS; STOMACH PH;

EID: 61449205249     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985-1001.
2. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004;10:1088-1094.
3. Koivisto TT, Rautelin HI, Voutilainen ME, Niemela SE, Heikkinen M, et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther. 2004;19:1009-1017.
4. Janssen MJ, Hendrikse L, de Boer SY, Bosboom R, de Boer WA, et al. Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. Neth J Med. 2006;64:191-195.
5. Petersen AM, Gjode P, Vinge OD, Jensen S, Krogfelt KA. Helicobacter pylori antimicrobial resistance and risk factors in Denmark 1998-2004: no need for concern? Helicobacter. 2006;11:210-211.
6. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol. 2005; 11:6009-6013.
7. John Albert M, Al-Mekhaizeem K, Neil L, Dhar R, Dhar PM, et al. High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. Aliment Pharmacol Ther. 2006;24:1359-1366.
8. Lwai-Lume L, Ogutu EO, Amayo EO, Kariuki S. Drug susceptibility pattern of Helicobacter pylori in patients with dyspepsia at the Kenyatta National Hospital, Nairobi. East Afr Med J. 2005;82:603-608.
9. Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW. Determinants of non-compliance with short term antibiotic regimens. Br Med J (Clin Res Ed). 1987;295:814-818.
10. Vakil N, Cutler A. Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Am J Gastroenterol. 1999;94:1197-1199.
11. Sherwood P, Wibawa J, Atherton J, Jordan N, Jenkins D, et al. Impact of acid secretion, gastritis and mucus thickness on gastric transfer of antibiotics in rats. Gut. 2002;51:490-494.
12. Goddard A. Review article: factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther. 1998;12:1175-1184.
13. Erah P, Goddard A, Barrett D, Shaw P, Spiller R. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39:5-12.
14. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten SJ, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol. 1998;28:383-393.
15. Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-1384.
16. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146:556-563.
17. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, et al. Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. Gut. 2007;56:772-781.
18. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825.
19. Vakil N, Vaira D. Sequential therapy for Helicobacter pylori: time to make the switch? JAMA. 2008;300:1346-1347.
20. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, et al. Esomeprazolebased Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000;95:3393-3398.
21. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562-567.
22. Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol. 1998;93:2106-2112.
23. Fennerty MB, Kovacs TO, Krause R, Haber M, Weissfeld A, er al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med. 1998;158:1651-1656.
24. Bochenek WJ, Peters S, Fraga PD, Wang W, Mack ME, et al; Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003;8:626-642.
25. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99-107.
26. Graham D, Yamaoka Y. Ethical considerations of comparing sequential and traditional anti-Helicobacter therapy. Ann Intern Med. 2007;147:434-435.
27. Sharma VK, Howden CW. A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection. J Clin Gastroenterol. 2004;38:326-331.
28. Delaney BC, Qume M, Moayyedi P, Logan RF, Ford AC, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ. 2008;336:651-654.
29. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by the Maastricht III consensus conference and a third line empirical regimen. Am J Gastroenterol. 2008 Sep 4; [Epub ahead of print].
30. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a single-centre study of 500 patients. Aliment Pharmacol Ther. 2008;27:346-354.
31. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology. 2002;123:1763-1769.
32. Calvet X, Ducons J, Guardlola J, Tito L, Andreu V, et al; Group for Eradication Studies from Catalonia and Aragon (Gresca). One-week triple vs quadruple therapy for Helicobacter pylori infection-a randomized trial. Aliment Pharmacol Ther. 2002;16:1261-1267.
33. O'Morain C, Borody T, Farley A, De Boer WA, Dallaire C, et al. International multicentre study. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther. 2003;17:415-420.
34. Gene E, Calvet X, Azagra R, Gisbert J. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 2003;17:1137-1143.
35. Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med. 2002;162:153-160.
36. Rinaldi V, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 1997;11:929-933.
37. Jafri N, Hormung C, Howden C. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naïve to treatment. Ann Intern Med. 2008;148:1-9.
38. Gatta L, Di Mario F, Zullo A, Vaira D. Errors in a meta-analysis of treatments for Helicobacter pylori infection. Ann Intern Med. 2008; 149:686.
39. Delgado J, Bujanda L, Gisbert P, Tito L, Calvet X, Castro M. Effectiveness of a 10-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol. 2008;103:2220-2223.
40. Wu D, Hsu P, Wu J, Opekun A, Graham D. Randomized controlled comparison of sequential and quadruple therapies for H. pylori infection. Gastroenterology. 2008;134:A24.
41. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488-496.
42. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24:1469-1474.
43. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther. 2007;26:1537-1542.